---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-250674"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2025-10-27T23:59:59+00:00"
generated_at: "2026-05-17T02:09:43.556922+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# FT819 SLE data: 10 patients show durable responses; expansion cohorts; pivotal study planned 2026

## Summary
- 10 SLE patients treated; 2 with lupus nephritis achieved CRR at 6 months; 1 in DORIS at 15 months.
- No dose-limiting toxicities, low-grade CRS, no ICANS or GvHD; supports same-day discharge plans.
- Initiated dose-expansion cohorts in AAV, IIM, and SSc; engaging FDA for registrational study design with pivotal study goal in 2026.
- Approximately 600 cryopreserved FT819 bags in inventory available for patient treatment.

## SEC filing metadata
- accession: 0001193125-25-250674
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2025-10-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000119312525250674/0001193125-25-250674-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000119312525250674/d36426d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-250674
- JSON: https://secwatch.observer/filing/0001193125-25-250674.json
- Plain text: https://secwatch.observer/filing/0001193125-25-250674.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.